- Home
- WLYB vs BEAM Comparison
WLYB vs BEAM Comparison
Compare WLYB & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- BEAM
- Stock Information
- Founded
- WLYB 1807
- BEAM 2017
- Country
- WLYB United States
- BEAM United States
- Employees
- WLYB N/A
- BEAM N/A
- Industry
- WLYB Books
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WLYB Consumer Discretionary
- BEAM Health Care
- Exchange
- WLYB Nasdaq
- BEAM Nasdaq
- Market Cap
- WLYB 2.0B
- BEAM 1.7B
- IPO Year
- WLYB N/A
- BEAM 2020
- Fundamental
- Price
- WLYB $39.94
- BEAM $17.46
- Analyst Decision
- WLYB
- BEAM Strong Buy
- Analyst Count
- WLYB 0
- BEAM 10
- Target Price
- WLYB N/A
- BEAM $48.56
- AVG Volume (30 Days)
- WLYB 116.0
- BEAM 2.4M
- Earning Date
- WLYB 09-04-2025
- BEAM 08-05-2025
- Dividend Yield
- WLYB 3.54%
- BEAM N/A
- EPS Growth
- WLYB N/A
- BEAM N/A
- EPS
- WLYB 1.53
- BEAM N/A
- Revenue
- WLYB $1,677,609,000.00
- BEAM $60,272,000.00
- Revenue This Year
- WLYB $1.45
- BEAM N/A
- Revenue Next Year
- WLYB $2.70
- BEAM $17.18
- P/E Ratio
- WLYB $25.55
- BEAM N/A
- Revenue Growth
- WLYB N/A
- BEAM N/A
- 52 Week Low
- WLYB $37.27
- BEAM $13.53
- 52 Week High
- WLYB $52.90
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- WLYB 39.96
- BEAM 39.16
- Support Level
- WLYB $41.30
- BEAM $16.65
- Resistance Level
- WLYB $42.70
- BEAM $21.40
- Average True Range (ATR)
- WLYB 0.00
- BEAM 1.00
- MACD
- WLYB 0.09
- BEAM -0.35
- Stochastic Oscillator
- WLYB 100.00
- BEAM 13.89
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.